WebVest Securities, Inc.
381 Park Avenue South
Suite 1316
New York, NY 10016
Science Based Fundamental Life Science Investment Research
- Cardiovascular
- Oncology
- Diabetes
- Infectious Disease
- Neurodegenerative Disease
WebVest provides fundamental science-driven proprietary research on smaller capitalization life science and medical device companies. Our strategy is to achieve market awareness of our research among both smaller institutions and the private individual investors who seek wealth creation and have an appreciation for novel treatments in the medical field. We use our research product to provide these investors with proprietary information which can lead to company share price appreciation and wealth accumulation.
Webvest Management and Advisors
WebVest has assembled an experienced team of professionals with an in-depth knowledge of investment banking, equity capital markets, and life science / medical device / specialty pharmaceuticals research.
George M. Bevis- Mr. Bevis has spent over twenty five years in the institutional equity capital markets In New York City, specifically at F Eberstadt and Co., Smith Barney and Lehman Brothers. His principal responsibilities were managing accounts in the sales and trading departments. In his last seven years, he was a Senior Managing Director of Institutional Sales and Trading of Advest.
Mr. Bevis has a BA in Economics from Adelphi University. gbevis@webvestsec.com
Andrew M. Sadosky- Mr. Sadosky is the founder and Managing Partner of Cerulean Advisors LLC, an investment banking and advisory firm. The firm raises growth capital and provides capital markets advice as well as financial/ strategic guidance to emerging healthcare companies. Mr. Sadosky has close to three decades of both investment banking and general business advisory experience. His transaction experience has emphasized the origination of public offerings, private placements of equity, and financial advisory engagements. Mr. Sadosky began his investment banking career at Credit Suisse First Boston (“CSFB”), initially as a generalist and subsequently as a member of the firm’s Technology Banking Group. During his tenure at CSFB, he received extensive debt and equity transaction experience with established technology and Fortune 500 companies. Mr. Sadosky subsequently managed financing/advisory transactions for small and mid-sized healthcare companies and developed his investment banking clientele as a senior banker during his tenures at Punk Ziegel, Advest, Gruntal, and The Maxim Group.asadosky@webvestsec.com
John M. Putnam, CFA – Mr. Putnam joined WebVest in January 2013 as Managing Director of Research and Senior Medical Device Analyst. Prior to joining WebVest, he was a Managing Director and a Supervisory Analyst at Capstone Investments where he co-managed a staff of 11 analysts, vendor relationships and regulatory affairs, and was one of four managing directors directly engaged in the day-to-day operations and setting the strategic direction of the firm. Mr. Putnam has also had tenures at Dawson James, Stanford Financial Group and was a principal and co-founder of Belmont Harbor Capital, a boutique investment research and merchant bank where he developed a proprietary research product that objectively analyzed the patent portfolio and competitive position of companies within a specific technology. This research methodology is critically important in developing competitive intelligence, clinical intelligence and setting research and development strategies.
Mr. Putnam has covered the Medical Devices and Technology industry for over 35 years. He was the first securities analyst to identify angioplasty and Women’s Health as major investment opportunities. During his tenure as a medical device analyst, Mr. Putnam has served in a similar capacity at such firms as Smith Barney, Wellington Management, L.F. Rothschild, Alex Brown & Sons, Adams, Harkness & Hill, and Gruntal. Mr. Putnam has been the lead analyst and provider of due diligence on more than 20 investment banking engagements. He is a Chartered Financial Analyst and a member of the Boston Security Analysts Society and holds FINRA Series 7, 24, 63, 86 and 87 licenses. jputnam@webvestsec.com
Cameron Durrant MD, DRCOG, DipCH, MRCGP, MBA- Dr. Durrant is an accomplished life science executive and entrepreneur who has functioned as a marketing, financing and business/corporate development professional with a strong medical/clinical base as an MD. He has operated successfully in the pharmaceutical industry for 22 years after having been in medical practice for eight years. He has particular expertise in the areas of infectious diseases, oncology, pediatrics, dermatology and CNS conditions, particularly Alzheimer’s disease. Dr. Durrant has served as board chairman and director and CEO or interim CEO, as well as CFO or Treasurer, for both private and public companies, including PediaMed Pharmaceuticals, Spherics, Anavex and PediatRx. Most recently, as a corporate officer of Hi-Tech Pharmacal and CEO of the ECR division, he was involved in the $640 million cash sale to Akorn and oversaw a turnaround of the division, increasing sales by 50% and achieving profitability within one year.
Dr. Durrant is a founding director of Bexion Pharmaceuticals and a board member of Alcyone Life Sciences. He has served as a founding investor, Chairman, CEO and CFO of PediatRx , Executive Chairman and CEO of Anavex, former Chairman of Pressure Point, former CEO of PediaMed Pharmaceuticals, former board member of Topaz Pharmaceuticals (acquired by Sanofi-Aventis) and a former founding investor in Prism Pharmaceuticals (acquired by Baxter). He has been an advisor to Cerulean Advisors, Saxa Private Equity Partners, Microsoft, Aprecia Pharmaceuticals, Pilgrim Software and PathXL. Dr. Durrant has also participated in creating four companies around targeted early-stage technologies with Cincinnati Children’s Hospital and assisted several private equity groups in their diligence efforts. He has raised over $60 million in venture, private equity, angel and high net worth financings.
Prior to becoming an entrepreneur, Dr. Durrant held sales, marketing, strategy, business development, planning and operational roles with Merck, GlaxoSmithKline, Pharmacia and Johnson & Johnson. He has launched or held commercial responsibility for seven brands which achieved over $1billion in annual sales and launched 20 other brands, many of which were category leaders.
Dr. Durrant earned an M.D. from the Welsh National School of Medicine, Cardiff, UK, a DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, a MRCGP from the Royal College of General Practitioners, London, UK, a DipCH from the Melbourne Academy, Australia and an MBA from Henley Management College, Oxford, UK. He was the 2005 winner of the Ernst and Young Ohio and Kentucky ‘Entrepreneur of the Year’ winner and a national finalist, named in the PharmaVoice 2005, 2006, 2007 and 2010 list of one of the ‘100 most inspiring people in the pharmaceutical industry’ and by Pharmaceutical Executive in 2008 as part of the ‘Change generation – young leaders to watch in pharma’.
Ben Chodor- Entrepreneur – Executive – Communicator – Technologist – Ben joined Sherpa Digital Media in November of 2013, as an Investor, Board Member and C0-CEO overseeing day to day operation of Sherpa’s West Coast and East Coast Professional Services division and Studio operation’s. Ben brings over 25 years of experience as a global leader in the world of on-line video and productio
He was most recently, Co-Founder & Ceo of Happtique of mobile health start-up & Founder of Stream57 a leading corporate streaming media company, and former Global head of Streaming & Virtual Events at InterCall, Ben Chodor was the tireless driving force behind the innovative streaming media & virtual events team. Ben has spent his career pioneering online communications through interactive and streaming content, and founded Stream57 on his wealth of experience merging the healthcare, financial services, streaming & technology fields. After selling his company to the InterCall/West corporation in December 2009, Ben was leading the development arm of streaming media, online technologies and virtual meetings space with his energetic and incomparable passion for technology, he was truly creating the future of interactive streaming & virtual communications. He was the driving force in acquiring Unisfair a leading Virtual Event company. His goal was to integrate Intercalls best of breed streaming technology with Unisfairs technology to create the best and largest Virtual Events organization in the world.
Ben joined Happtique as it’s CEO & Co-Founder and believes that mHealth is a key to the future of Healthcare and Happtique had positioned itself as the true game changer, in the efforts to connect providers, patients and technology. Ben is also a highly sought after mHealth, Technology & Digital Media, speaker and moderator, Ben has presented at major conferences around the country and has had the honor of testifying before the United States Congress. Ben also hosted mHealth Zone Live, (www.mhealthzone.com) a weekly radio show that showcases the latest on mHealth apps and technology. Launched in 2012, mHealth Zone Live has had over one million listeners and was a top 300 show on Blogtalkradio.
As well, Ben is very proud to serve as a mentor for Blueprint, a startup accelerator based in NYC, and as an advisor to several healthcare and digital media companies and start-up’s.
He is also a co-founder & investor in Clopsi a company that is about doing more with your photo’s, in the Consumer, Enterprise and Healthcare space.
He splits his time living in New Jersey & New York City with his wife, Julie, and their twins, Rachel and Zachary. Ben is avid reader and fitness & yoga nut, who wakes up most morning about 4am in order to check emails and get his workout in before his day begins.
Leave a Reply